title: Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
abstract: BACKGROUND
  Myc-positive B-cell non-Hodgkin lymphoma (NHL) with or without a B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) rearrangement is associated with inferior progression-free survival (PFS) and overall survival (OS). In this study, the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University.
  
  
  METHODS
  All patients who had non-Burkitt, aggressive B-cell NHL from 2008 to 2011 were assessed for the t(14;18) translocation and for v-myc avian myelocytomatosis viral oncogene homolog (CMYC) rearrangements at diagnosis, and all myc-positive patients were included in the current analysis. Associations with clinical characteristics were described, and univariable and multivariable models were used to assess correlations between clinical variables and outcomes.
  
  
  RESULTS
  Of 49 myc-positive patients, 29 patients also had BCL2 rearrangements (double-hit NHL). No patients underwent autologous stem cell transplantation in first remission. For all myc-positive patients, the median PFS was 16.6 months, and the median OS was 37.7 months. For patients who had double-hit NHL, the median PFS was 8 months, and the median OS was 12.5 months; whereas the median PFS and OS were not reached for myc-positive patients. A complete response (CR) after front-line therapy, the presence of t(14;18), International Prognostic Index (IPI) group, and age were associated with PFS; whereas only the achievement of a CR and age >60 years were associated with OS in the multivariable setting. The median PFS was 3.3 months, and the median and OS was 7.0 months for patients who did not attain a CR; and the medians were not reached for patients who achieved a CR (P < .00001).
  
  
  CONCLUSIONS
  The achievement of a CR with front-line therapy is associated with a prolonged PFS and OS in patients with myc-positive NHL, even after adjusting for type of initial therapy, histology, age, IPI, or the presence of a concurrent BCL2 translocation.
authors.affiliation: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, Ohio.
authors.forename: Jonathon B
authors.initials: JB
authors.lastname: Cohen
authors.forename: Susan M
authors.initials: SM
authors.lastname: Geyer
authors.forename: Gerard
authors.initials: G
authors.lastname: Lozanski
authors.forename: Weiqiang
authors.initials: W
authors.lastname: Zhao
authors.forename: Nyla A
authors.initials: NA
authors.lastname: Heerema
authors.forename: Nathan C
authors.initials: NC
authors.lastname: Hall
authors.forename: Veena A
authors.initials: VA
authors.lastname: Nagar
authors.forename: Jessica A
authors.initials: JA
authors.lastname: Hemminger
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Jones
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Porcu
authors.forename: Beth A
authors.initials: BA
authors.lastname: Christian
authors.forename: Robert A
authors.initials: RA
authors.lastname: Baiocchi
authors.forename: Kami J
authors.initials: KJ
authors.lastname: Maddocks
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Flynn
authors.forename: Steven M
authors.initials: SM
authors.lastname: Devine
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D019254:Genes, bcl-2; D006801:Humans; D060828:Induction Chemotherapy; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000627:therapeutic use; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis*; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: B-cell lymphoma; C-myc genes; immunoglobulin heavy chain genes; non-Hodgkin lymphoma